To further investigate whether VPS34 inhibition activates a type I IFN response in cancer cells, we treated human RCC A‐498 and murine melanoma B16‐F10 cells with VPS34i SB02024 or SAR405 [12]. This evidence concerns the gene PIK3C3 and renal cell carcinoma.